A landmark study published June 2 in Regional Anesthesia & Pain Medicine reveals that GLP-1 receptor agonist drugs—widely used for diabetes and weight loss—may slash the long-term need for knee replacement surgery by nearly 5 percentage points for some patients. The findings, drawn from a global database of 6.8 million adults with knee osteoarthritis, suggest these drugs could prevent thousands of surgeries annually in the US and UK alone.
More than 300 million people worldwide live with osteoarthritis, a degenerative joint disease that often leads to knee replacement surgery as the only viable option. Yet, for the first time, researchers have found that sustained use of GLP-1 drugs—especially the newer agents semaglutide and tirzepatide—may not only ease pain but also delay or prevent the need for surgery. The implications for public health and healthcare systems are profound, potentially reshaping how osteoarthritis is managed in an aging, increasingly obese population.
How GLP-1 Drugs May Change the Trajectory of Knee Osteoarthritis
The study, led by researchers at the University of Maryland School of Medicine, analyzed anonymized health records from the TriNetX Global Research Network, tracking over 42,000 patients with knee osteoarthritis who had been prescribed GLP-1 drugs for at least one year. The results were striking: after just one year of treatment, the cumulative risk of knee replacement surgery dropped by 1.4 percentage points at the three-year mark, rising to nearly 3 percentage points by year eight. For those taking the newer drugs—semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)—for three years, the risk reduction reached nearly 5 percentage points by year eight.
These findings suggest that GLP-1 drugs may exert effects beyond weight loss, potentially including direct anti-inflammatory and cartilage-protective benefits. As The Guardian reports, the study authors speculate that if all eligible patients with knee arthritis and obesity or metabolic disease took semaglutide or tirzepatide for three years, up to 14,400 fewer knee replacements could occur annually in the US and more than 1,500 fewer in the UK.
What makes this study unique is its focus on real-world data, rather than controlled trials. The researchers matched patients on key factors like age, sex, BMI, and comorbidities, reducing the likelihood that baseline differences explained the results. Yet, the study’s observational nature means it cannot prove causality—only association. As the authors note, “more robust prospective studies incorporating defined patient phenotypes, GLP-1 dosing and duration, and objective measures of knee OA progression are required to confirm these associations and guide clinical care.”
Why Longer Use and Newer Drugs Make the Biggest Difference
The study’s most compelling finding is the clear dose-response relationship: the longer patients took GLP-1 drugs, and the newer the drug, the greater the reduction in knee replacement risk. This pattern aligns with preclinical evidence suggesting these drugs may modulate joint tissue and provide analgesic benefits independent of weight loss.
According to MedPage Today, the authors emphasize that the mechanisms behind these associations remain unclear. Were patients on GLP-1 drugs more likely to adopt healthier lifestyles overall? Or do these drugs have direct biological effects on joint health? The data cannot answer these questions definitively, but the trend is undeniable: sustained use of GLP-1 drugs correlates with a significantly lower incidence of knee replacement surgery.
Mark Bowditch, a consultant knee surgeon and immediate past president of the British Orthopaedic Association, cautioned that the findings do not prove these drugs prevent surgery outright. However, he acknowledged the possibility of “direct anti-inflammatory and possibly cartilage-protective effects of GLP-1 receptor agonists that operate through weight-independent mechanisms.” This opens the door to a new paradigm: GLP-1 drugs as a complementary strategy in non-surgical knee osteoarthritis management.
What the Numbers Mean for Patients and Healthcare Systems
The potential impact of these findings is staggering. In the US alone, over 14 million people live with knee osteoarthritis, and more than 120,000 knee replacements are performed annually in the UK. If even a fraction of these patients could avoid surgery through GLP-1 treatment, the cost savings and quality-of-life improvements would be transformative.
- 1.4 percentage points: Lower risk of knee replacement after 1 year of GLP-1 treatment at the 3-year follow-up.
- 2.8 percentage points: Lower risk after 1 year of treatment at the 8-year follow-up.
- 4.7 percentage points: Lower risk after 3 years of treatment with newer agents (semaglutide, tirzepatide) at the 8-year follow-up.
- 14,400: Estimated fewer knee replacements annually in the US if all eligible patients took newer GLP-1 drugs for 3 years.
- 1,500: Estimated fewer knee replacements annually in the UK under the same conditions.
The study’s authors highlight that these reductions are “consistent with the possibility of effects beyond symptomatic relief or weight loss alone.” This suggests that GLP-1 drugs might not just slow the progression of osteoarthritis but could also modify the disease itself, a prospect that has long eluded researchers.
The Big Questions: What Comes Next?
The study’s observational nature leaves critical questions unanswered. Are the benefits of GLP-1 drugs on knee osteoarthritis driven by weight loss, direct joint protection, or a combination of both? Could these drugs be used as a first-line treatment for osteoarthritis, or are they best reserved for patients with obesity or metabolic disease? And, perhaps most importantly, how will healthcare systems integrate these findings into clinical practice?
As AOL.com notes, the study authors call for more robust prospective trials to confirm these associations and guide clinical care. Until then, the findings offer a tantalizing glimpse into a future where GLP-1 drugs could play a pivotal role in managing osteoarthritis, potentially reducing the burden on patients and healthcare systems alike.
For now, the message is clear: GLP-1 drugs may be more than just a tool for weight loss and diabetes management. They could represent a game-changing strategy for preserving joint health and delaying the need for invasive surgery. But the journey from association to action—and from real-world data to clinical guidelines—has just begun.
Consult your healthcare provider for personalized medical advice.
